Vaxcyte, Inc. PCVX Business Segments — Acquired manufacturing rights

Similar metrics at other companies

MIRMReportable Segment — Acquired in-process research and development

$726.3M+14,426%

IMVTReportable Segment — Acquired in-process research and development

$0—

NBIXReportable Segment — Acquired in-process research and development

$21.2M+21,100%

LLYReportable Segment — Acquired in-process research and development

$584M-62.8%

SITMReportable Segment — Acquisition related costs

$7.62M+388%

ROIVReportable Segment — Acquired in-process research and development

$0—

Questions, answered.

What is Vaxcyte, Inc.'s business segments — acquired manufacturing rights?

Vaxcyte, Inc. (PCVX) reported business segments — acquired manufacturing rights of $0 in Q4 2025.

What is the long-term trend for Vaxcyte, Inc.'s business segments — acquired manufacturing rights?

Over 3 years (2022 to 2025), Vaxcyte, Inc.'s business segments — acquired manufacturing rights has grown at a -100.0% compound annual growth rate (CAGR), from $23M to $0.

What does business segments — acquired manufacturing rights mean?

This metric tracks the costs associated with the acquisition of intellectual property or contractual rights related to the manufacturing processes of the segment's products. It reflects strategic investments made to secure supply chain capabilities or proprietary production technologies. These expenditures are essential for transitioning from clinical development to commercial-scale manufacturing.